RESOLVE

MRD guided treatment

RESOLVE

MRD guided treatment

The RESOLVE Consortium relies on expert networks and patient advocacy partnerships to establish the predictive value of MRD in AML/CLL patients. This affordable, minimally-invasive biomarker aims to guide consolidation therapy intensity, improve quality of life, and reduce costs.

The Project

Welcome to the RESOLVE Project: Optimizing Leukemia Treatment – The RESOLVE Consortium establishes MRD as a key biomarker for guiding AML and CLL treatment. By developing a patient registry, standardizing MRD analysis, and conducting a multinational trial, we strive to improve patient outcomes.

Learn more

Consortium

The RESOLVE Project Consortium is a dynamic collaboration of 22 leading institutions from seven European countries and Israel, united to advance medical knowledge and improve patient outcomes. The consortium establishes MRD as a treatment-guiding biomarker for AML and CLL. With substantial EU funding, our work promises to enhance patient quality of life and reduce healthcare costs across Europe.

Learn more

Patients

Empowering Patients with Personalized Care for Better Outcomes: The RESOLVE Project is dedicated to improving treatment for AML and CLL patients across Europe. By developing a platform for routine clinical practice, we help medical staff to assess individual relapse risk and avoid overtreatment. Our goal is to ensure all patients have access to MRD testing within national healthcare systems. The RESOLVE trial explores a reduction in treatment intensity for MRD-negative patients, aiming to minimize side effects, lower economic burden, and enhance quality of life.

Learn more

Consortium

The RESOLVE Project Consortium is a dynamic collaboration of 22 leading institutions from seven European countries and Israel, united to advance medical knowledge and improve patient outcomes. The consortium establishes MRD as a treatment-guiding biomarker for AML and CLL. With substantial EU funding, our work promises to enhance patient quality of life and reduce healthcare costs across Europe.

Learn more

Patients

Empowering Patients with Personalized Care for Better Outcomes: The RESOLVE Project is dedicated to improving treatment for AML and CLL patients across Europe. By developing a platform for routine clinical practice, we help medical staff to assess individual relapse risk and avoid overtreatment. Our goal is to ensure all patients have access to MRD testing within national healthcare systems. The RESOLVE trial explores a reduction in treatment intensity for MRD-negative patients, aiming to minimize side effects, lower economic burden, and enhance quality of life.

Learn more

If you want to participate in the project or want more information, please contact us.

Contact

Partners and Collaborators

The RESOLVE Consortium brings together leading partners from multiple disciplines and will be supported by expert groups like ELN-DAVID, ALAN, CLLAN, and EHA-SWG Quality of Life & Symptoms.